This is a working overview of reverse-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-13 and is reviewed periodically as new material appears.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | 95 per cent or higher by RP-HPLC | Tighter grades reported near 98 per cent |
| Identity confirmation | Mass match by LC-MS | Observed mass compared with sequence-derived mass |
| Storage after dissolution | 2–8 °C, protected from light | Short-term use; avoid repeated freeze–thaw |
| Main degradation routes | Hydrolysis, oxidation, aggregation | Backbone and side-chain susceptibility in solution |
| Common diluents | Sterile water or bacteriostatic water | Choice depends on assay and sterility needs |
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
=== After birth === At birth, the baby's lungs are filled with fluid secreted by the lungs and are not inflated. After birth the infant's central nervous system reacts to the sudden change in temperature and environment. This triggers the first breath, within about ten seconds after delivery. Before birth, the lungs are filled with fetal lung fluid. After the first breath, the fluid is quickly absorbed into the body or exhaled. The resistance in the lung's blood vessels decreases giving an increased surface area for gas exchange, and the lungs begin to breathe spontaneously. This accompanies other changes which result in an increased amount of blood entering the lung tissues. At birth, the lungs are very undeveloped with only around one sixth of the alveoli of the adult lung present. The alveoli continue to form into early adulthood, and their ability to form when necessary is seen in the regeneration of the lung. Alveolar septa have a double capillary network instead of the single network of the developed lung. Only after the maturation of the capillary network can the lung enter a normal phase of growth. Following the early growth in numbers of alveoli there is another stage of the alveoli being enlarged.
Peptide mass fingerprinting (PMF), also known as protein fingerprinting, is an analytical technique for protein identification in which the unknown protein of interest is first cleaved into smaller peptides, whose absolute masses can be accurately measured with a mass spectrometer such as MALDI-TOF or ESI-TOF. The method was developed in 1993 by several groups independently. The peptide masses are compared to either a database containing known protein sequences or even the genome. This is achieved by using computer programs that translate the known genome of the organism into proteins, then theoretically cut the proteins into peptides, and calculate the absolute masses of the peptides from each protein. They then compare the masses of the peptides of the unknown protein to the theoretical peptide masses of each protein encoded in the genome. The results are statistically analyzed to find the best match. The advantage of this method is that only the masses of the peptides have to be known. A disadvantage is that the protein sequence has to be present in the database of interest. Additionally most PMF algorithms assume that the peptides come from a single protein. The presence of a mixture can significantly complicate the analysis and potentially compromise the results. Typical for the PMF-based protein identification is the requirement for an isolated protein. Mixtures exceeding a number of 2–3 proteins typically require the additional use of MS/MS-based protein identification to achieve sufficient specificity of identification.
The Hollywood Reporter's Stephen Dalton wrote that the "dark, ironic, very British humour of the original strip" was largely absent from the film and that "[t]he limited location, computer game-style plot and muted humour" of the film might disappoint some fans of the comic. Dalton also said that Urban's performance, while close to the comic, lacked something. Overall Dalton said, "[p]itched at the right level to please original fans, but still slick and accessible enough to attract new ones, [Dredd] feels like a smart and muscular addition to the sci-fi action genre." The visual effects and slow-motion sequences induced by Slo-Mo received broad praise. Berkshire said that they are notable and eye-catching with "impressively utilised 3D." Hewitt said the visuals were "genuinely surreal splashes of heightened colour that ... don't outstay their welcome. The film's use of 3D is often excellent (including the credits) and it really comes to life in the Slo-mo scenes". Dalton said the film "constantly impresses on a visual level, with a gritty style more akin to cult hits like District 9 or 28 Days Later than to standard Hollywood comic-book blockbusters." Dalton said, "[Mantle's] first venture into 3D is a blaze of saturated colours, gorgeous high-resolution close-ups and dazzling slow-motion sequences." Dredd won The Art of 3D award at the 2013 Empire Awards, and was nominated for Best British Film and Best Science-fiction/Fantasy. Judge Dredd creator John Wagner, who had been critical of the 1995 adaptation, gave a positive review of Dredd. He said: "I liked the movie.
He was only arrested in 2006 after he returned to Russia, believing that the ten-year old case was closed. Felshtinsky and Pribylovsky claimed that Russia's security services, which had access to the chemical agent, had framed Khutsishvili for the murder, and that the security services had organised the murder on the orders of a senior Russian state official. Boris Kuznetsov, who represented Khutsishvili and believed in his innocence, blames "rogue intelligence officers". Leonid Rink, an employee of GosNIIOKhT, received a one-year suspended sentence for selling Novichok agents to unnamed buyers "of Chechen ethnicity" soon after the poisoning of Kivelidi and Izmailova.
The report concluded that a final determination of the origin was unlikely without cooperation from the Chinese government, saying their prior lack of transparency "reflect[ed] in part China's government's own uncertainty about where an investigation could lead, as well as its frustration that the international community is using the issue to exert political pressure on China." Chinese foreign ministry spokesman Wang Wenbin said that the US intelligence report was "unscientific and has no credibility". On 23 May 2021, The Wall Street Journal reported that a previously undisclosed US intelligence report stated that three researchers from the Wuhan Institute of Virology became ill enough in November 2019 to seek hospital care. The report did not specify what the illness was. Officials familiar with the intelligence differed as to the strength to which it corroborates the hypothesis that the virus responsible for COVID-19 was leaked from the WIV. The WSJ report notes that it is not unusual for people in China to go to the hospital with uncomplicated influenza or common cold symptoms. Yuan Zhiming, director of the WIV's Wuhan National Biosafety Laboratory, responded in the Global Times, a Chinese state media outlet, that the "claims are groundless". Marion Koopmans, a member of the WHO study team, described the number of flu-like illnesses at the WIV in 2019 as "completely normal". Workers at the WIV must provide yearly serum samples. WIV virologist Shi Zhengli said in 2020 that, based on an evaluation of those serum samples, all staff tested negative for COVID-19 antibodies.
Sources: en.wikipedia.org
=== Bio-based electronics and energy storage === Nanocellulose can pave the way for a new type of "bio-based electronics" where interactive materials are mixed with nanocellulose to enable the creation of new interactive fibers, films, aerogels, hydrogels and papers. E.g. nanocellulose mixed with conducting polymers such as PEDOT:PSS show synergetic effects resulting in extraordinary mixed electronic and ionic conductivity, which is important for energy storage applications. Filaments spun from a mix of nanocellulose and carbon nanotubes show good conductivity and mechanical properties. Nanocellulose aerogels decorated with carbon nanotubes can be constructed into robust compressible 3D supercapacitor devices. Structures from nanocellulose can be turned into bio-based triboelectric generators and sensors. In April 2013 breakthroughs in nanocellulose production, by algae, were announced at an American Chemical Society conference, by speaker R. Malcolm Brown, Jr., Ph.D, who has pioneered research in the field for more than 40 years, spoke at the First International Symposium on Nanocellulose, part of the American Chemical Society meeting. Genes from the family of bacteria that produce vinegar, Kombucha tea and nata de coco have become stars in a project — which scientists said has reached an advanced stage - that would turn algae into solar-powered factories for producing the "wonder material" nanocellulose.
Mitchell, Robert Wayne (2003). Political Shifts During the Carter Years: North Carolina Conservatism and Stokes County's Perception of Tobacco, The Economy, and Foreign Policy (PDF) (Thesis). North Carolina State University. Retrieved November 10, 2020.
structural protein Any protein which contributes to the mechanical shape and structure of cells, organelles, or tissues (e.g. collagen and actin), as distinguished from proteins which serve some other purpose, such as enzymes. This distinction is not well-defined, however, as many proteins have both structural and non-structural roles.
=== Physicochemical factors affecting carbon nanotube toxicity === Numerous studies have identified key physicochemical properties of carbon nanotubes (CNTs) that influence their biological interactions and toxicological profiles in both in vitro and in vivo systems: Aspect ratio, length, and rigidity: Long and rigid CNTs exhibit increased biopersistence and are strongly associated with fibrogenesis, through the activation of the Smad2/3 and ERK1/2 signaling pathways. Their high aspect ratio and fiber-like morphology, reminiscent of asbestos, can impair macrophage-mediated clearance, and induce inflammation, fibrotic tissue remodeling, granuloma formation, and even DNA damage. Multi-walled carbon nanotubes (MWCNTs) with lengths ranging from approximately 0.5 to 10 μm have been implicated in severe pulmonary conditions, including asbestosis-like fibrosis and mesothelioma. Similarly, single-walled carbon nanotubes (SWCNTs) exceeding 10 μm in length can induce granulomatous lesions. In contrast, shorter SWCNTs—particularly those under 300 nm and well-dispersed—are more readily cleared from the body via renal and biliary excretion pathways. These shorter, purified SWCNTs have demonstrated significantly reduced inflammatory and cytotoxic responses and, to date, lack conclusive evidence of carcinogenicity. Aggregation state: The aggregation state of CNTs refers to their propensity to cluster into bundles or agglomerates, primarily driven by van der Waals forces and electrostatic interactions.
Stephanie Kate Howard, Moves and Operations Manager, Buckingham Palace Re-servicing Programme, Royal Household. Adelaide Georgina Gray Izat, Paintings Conservator, Royal Collection, Royal Household. Daniel James Kevin Johnson, Archbishop of Canterbury's Coronation Planning Director, on the occasion of the Coronation of Their Majesties The King and The Queen. Kevin Malkin, Detective Constable, Metropolitan Police Service. For services to Royalty Protection. Louise Michelle Walker-Pickett, Purchasing and Cost Control Co- ordinator, Royal Household. Nicola Jane Pritchard, Property Project Manager, Windsor Castle. Warrant Officer Class 1 David Alexander Roper, Grenadier Guards, 25131200; Superintending Clerk, Household Division, on the occasion of the Coronation of Their Majesties The King and The Queen. Warrant Officer Class 2 Julian Philip Desmond Sandford, Royal Corps of Army Music, 25152991; Sergeant Major, Band of the Household Cavalry, on the occasion of the Coronation of Their Majesties The King and The Queen. Christopher Charles Savage, lately Messenger Sergeant Major, The King's Body Guard of the Yeomen of the Guard. Derrick Andrew Scott, Royal Borough of Windsor and Maidenhead, on the occasion of the Coronation Concert. Thomas Nicholas McKinlay Service, lately Acting Chief Operating Officer, Household of The Prince and Princess of Wales. Elizabeth Fiona St Clair, Sergeant, Metropolitan Police Service. For services to Royalty and Specialist Protection. Kathryn Elizabeth Stone, Paper Conservator, Royal Collection, Royal Household.
Sources: en.wikipedia.org
Purity is normally given as a percentage from reversed-phase HPLC, calculated as the main peak area relative to total peak area. Research-grade material is commonly specified at 95 per cent or higher, with tighter specifications available. The number is method-dependent and should be read alongside the chromatogram.
Mass spectrometry is the standard check, comparing the measured mass with the mass calculated from the published amino acid sequence. Retention time on HPLC and peptide mapping provide supporting evidence. Sequence-level confirmation separates it from closely related analogues.
Dry powder is chemically stable enough for freezer storage over long periods. In solution, water participates directly in hydrolysis and enables aggregation, so breakdown accelerates. Cold, dark, short-term storage after dissolution reflects that difference.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.